Abstract
Zavegepant is the first intranasal calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine and offers a new nonoral option for patients. This article reports the findings of a comprehensive literature review to assess zavegepant's safety and effectiveness. Evidence synthesis involved reporting findings from clinical trials and evaluating comparative effectiveness. This review was prepared by the University of Connecticut School of Pharmacy Academy of Managed Care Pharmacy (AMCP) Student Chapter. The student author group won the AMCP National Pharmacy and Therapeutics competition for their zavegepant product review in March 2024.